- One revisited an original analysis conducted back in 2007, adding new data from studies completed in the last three years. The increase in heart attack risk compared to placebo shrinks from 43% to 28%, compared to placebo. The increase in cardiac death is no longer even close to statistically significant. According to the analysis, 37 patients would have to be treated with Avandia for one year to be harmed.
Researchers for the National Institutes of Health presented results from a clinical trial not specifically designed to evaluate Avandia by itself. They found no increase in the risk of heart attack or cardiovascular death for patients on Avandia. In fact, the patients taking the drug had fewer heart attacks or cardiac deaths, though that result wasn't statistically significant.
So what does this mean for the FDA as well as the drug? There were lessons from the FDA's request to withdraw Bextra several years ago, and to me the political pressure will be perhaps to issue warnings - leaving uncertainty with consumers across the US who will read more and more about the risks of Avandia. Certainly the FDA has to know that a recall of this blockbuster drug will have long reaching legal ramifications and likely bring a deluge of ore more lawsuits alleging injury.
What will happen? Stay tuned.